12:00 AM
 | 
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Nulojix belatacept regulatory update

The Scottish Medicines Consortium recommended against the use of Nulojix belatacept from Bristol-Myers on the National Health Service (NHS) in Scotland to prevent organ rejection in adult...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >